The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.
R. Bahleda
No relevant relationships to disclose
J. Soria
Consultant or Advisory Role - Boehringer Ingelheim
Y. Berge
No relevant relationships to disclose
C. Massard
No relevant relationships to disclose
S. Wind
Employment or Leadership Position - Boehringer Ingelheim
M. M. Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
F. Fleischer
Employment or Leadership Position - Boehringer Ingelheim
H. De-Montserrat
Employment or Leadership Position - Boehringer Ingelheim
F. Solca
Employment or Leadership Position - Boehringer Ingelheim
I. Tschoepe
Employment or Leadership Position - Boehringer Ingelheim
J. Delord
Consultant or Advisory Role - Roche